HIPK2 inhibits cell metastasis and improves chemosensitivity in esophageal squamous cell carcinoma

Zhang,Zhen; Wen,Penghaο; Li,Fangfang; Yao,Chuanshan; Wang,Tongfu; Liang,Bing; Yang,Qingle; Ma,Lei; He,Limin

doi:10.3892/etm.2017.5468

HIPK2 inhibits cell metastasis and improves chemosensitivity in esophageal squamous cell carcinoma

Authors:
- Zhen Zhang
- Penghaο Wen
- Fangfang Li
- Chuanshan Yao
- Tongfu Wang
- Bing Liang
- Qingle Yang
- Lei Ma
- Limin He
View Affiliations

Affiliations: Department of Clinical Oncology, The First People's Hospital of Nanyang, Nanyang, Henan 473000, P.R. China, Department of Clinical Oncology, The Affiliated Nanshi Hospital of Henan University, Nanyang, Henan 473000, P.R. China
Published online on: November 8, 2017 https://doi.org/10.3892/etm.2017.5468
Pages: 1113-1118

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive and lethal malignancies worldwide. At present, the underlying mechanisms of ESCC development and progression are poorly understood. Previous studies have demonstrated that homeodomain‑interacting protein kinase‑2 (HIPK2) serves an important role in cancer biology, particularly in proliferation and metastasis. However, the role of HIPK2 in ESCC cells remains unclear. In the current study, the expression of HIPK2 in ESCC specimens, adjacent non‑cancerous tissues and cell lines was assessed using reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). The effects of HIPK2 on cell metastasis, epithelial‑mesenchymal transition (EMT) and proliferation were studied using a Transwell assay, RT‑qPCR and a Cell Counting Kit‑8 assay, respectively. The results indicated that HIPK2 expression was downregulated in ESCC specimens and cell lines, and HIPK2 expression was associated with tumor invasion and lymph node metastasis. Functional studies demonstrated that HIPK2 overexpression inhibited cell metastasis and EMT. Furthermore, HIPK2 overexpression suppressed cell viability during cisplatin treatment. These results suggest that HIPK2 serves an important role in regulating metastasis and the chemosensitivity of ESCC cells, implicating the potential application of HIPK2 in ESCC therapy.

View Figures

View References

1	Wang LD, Zhou FY, Li XM, Sun LD, Song X, Jin Y, Li JM, Kong GQ, Qi H, Cui J, et al: Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. Nat Genet. 42:759–763. 2010. View Article : Google Scholar : PubMed/NCBI
2	Hongo M, Nagasaki Y and Shoji T: Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol. 24:729–735. 2009. View Article : Google Scholar : PubMed/NCBI
3	Morita M, Kumashiro R, Kubo N, Nakashima Y, Yoshida R, Yoshinaga K, Saeki H, Emi Y, Kakeji Y, Sakaguchi Y, et al: Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: Epidemiology, clinical findings, and prevention. Int J Clin Oncol. 15:126–134. 2010. View Article : Google Scholar : PubMed/NCBI
4	Brown LM, Hoover R, Silverman D, Baris D, Hayes R, Swanson GM, Schoenberg J, Greenberg R, Liff J, Schwartz A, et al: Excess incidence of squamous cell esophageal cancer among US Black men: Role of social class and other risk factors. Am J Epidemiol. 153:114–122. 2001. View Article : Google Scholar : PubMed/NCBI
5	Pennathur A, Gibson MK, Jobe BA and Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013. View Article : Google Scholar : PubMed/NCBI
6	Nardinocchi L, Puca R, Sacchi A, Rechavi G, Givol D and D'Orazi G: Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1alpha. PLoS One. 4:e68192009. View Article : Google Scholar : PubMed/NCBI
7	Di Stefano V, Blandino G, Sacchi A, Soddu S and D'Orazi G: HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function. Oncogene. 23:5185–5192. 2004. View Article : Google Scholar : PubMed/NCBI
8	Bon G, Di Carlo SE, Folgiero V, Avetrani P, Lazzari C, D'Orazi G, Brizzi MF, Sacchi A, Soddu S, Blandino G, et al: Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression. Cancer Res. 69:5978–5986. 2009. View Article : Google Scholar : PubMed/NCBI
9	Ann EJ, Kim MY, Yoon JH, Ahn JS, Jo EH, Lee HJ, Lee HW, Kang HG, Choi DW, Chun KH, et al: Tumor suppressor HIPK2 regulates malignant growth via phosphorylation of Notch1. Cancer Res. 76:4728–4740. 2016. View Article : Google Scholar : PubMed/NCBI
10	Jin Y, Ratnam K, Chuang PY, Fan Y, Zhong Y, Dai Y, Mazloom AR, Chen EY, D'Agati V, Xiong H, et al: A systems approach identifies HIPK2 as a key regulator of kidney fibrosis. Nat Med. 18:580–588. 2012. View Article : Google Scholar : PubMed/NCBI
11	Pistritto G, Puca R, Nardinocchi L, Sacchi A and D'Orazi G: HIPK2-induced p53Ser46 phosphorylation activates the KILLER/DR5-mediated caspase-8 extrinsic apoptotic pathway. Cell Death Differ. 14:1837–1839. 2007. View Article : Google Scholar : PubMed/NCBI
12	Puca R, Nardinocchi L, Pistritto G and D'Orazi G: Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol. 109:403–410. 2008. View Article : Google Scholar : PubMed/NCBI
13	Lazzari C, Prodosmo A, Siepi F, Rinaldo C, Galli F, Gentileschi M, Bartolazzi A, Costanzo A, Sacchi A, Guerrini L and Soddu S: HIPK2 phosphorylates ΔNp63α and promotes its degradation in response to DNA damage. Oncogene. 30:4802–4813. 2011. View Article : Google Scholar : PubMed/NCBI
14	Nodale C, Sheffer M, Jacob-Hirsch J, Folgiero V, Falcioni R, Aiello A, Garufi A, Rechavi G, Givol D and D'Orazi G: HIPK2 downregulates vimentin and inhibits breast cancer cell invasion. Cancer Biol Ther. 13:198–205. 2012. View Article : Google Scholar : PubMed/NCBI
15	Tan M, Gong H, Zeng Y, Tao L, Wang J, Jiang J, Xu D, Bao E, Qiu J and Liu Z: Downregulation of homeodomain-interacting protein kinase-2 contributes to bladder cancer metastasis by regulating Wnt signaling. J Cell Biochem. 115:1762–1767. 2014. View Article : Google Scholar : PubMed/NCBI
16	Rice TW, Blackstone EH and Rusch VW: 7th edition of the AJCC cancer staging Manual: Esophagus and esophagogastric junction. Ann Surg Oncol. 17:1721–1724. 2010. View Article : Google Scholar : PubMed/NCBI
17	Han T, Zhu X, Wang J, Zhao H, Ma Q, Zhao J, Qiu X and Fan Q: Establishment and characterization of a cisplatin-resistant human osteosarcoma cell line. Oncol Rep. 32:1133–1139. 2014.PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Zeisberg M and Neilson EG: Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 119:1429–1437. 2009. View Article : Google Scholar : PubMed/NCBI
20	Akita H, Doki Y, Miyata H, Hirao T, Yano M, Takachi K, Miyashiro I, Sasaki Y, Ishikawa O, Ohigashi H and Imaoka S: Clinical significance of the second cycle response to cisplatin-based chemotherapy as preoperative treatment for esophageal squamous cell carcinoma. J Surg Oncol. 93:401–409. 2006. View Article : Google Scholar : PubMed/NCBI
21	Liu A, Zhu J, Wu G, Cao L, Tan Z, Zhang S, Jiang L, Wu J, Li M, Song L and Li J: Antagonizing miR-455-3p inhibits chemoresistance and aggressiveness in esophageal squamous cell carcinoma. Mol Cancer. 16:1062017. View Article : Google Scholar : PubMed/NCBI
22	Lin J, Zhang Q, Lu Y, Xue W, Xu Y, Zhu Y and Hu X: Downregulation of HIPK2 increases resistance of bladder cancer cell to cisplatin by regulating Wip1. PLoS One. 9:e984182014. View Article : Google Scholar : PubMed/NCBI
23	Cheng Y, Al-Beiti MA, Wang J, Wei G, Li J, Liang S and Lu X: Correlation between homeodomain-interacting protein kinase 2 and apoptosis in cervical cancer. Mol Med Rep. 5:1251–1255. 2012.PubMed/NCBI
24	D'Orazi G, Sciulli MG, Di Stefano V, Riccioni S, Frattini M, Falcioni R, Bertario L, Sacchi A and Patrignani P: Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells. Clin Cancer Res. 12:735–741. 2006. View Article : Google Scholar : PubMed/NCBI
25	Hsu WH, Hsu PK, Hsieh CC, Huang CS and Wu YC: The metastatic lymph node number and ratio are independent prognostic factors in esophageal cancer. J Gastrointest Surg. 13:1913–1920. 2009. View Article : Google Scholar : PubMed/NCBI
26	Hosch SB, Stoecklein NH, Pichlmeier U, Rehders A, Scheunemann P, Niendorf A, Knoefel WT and Izbicki JR: Esophageal cancer: The mode of lymphatic tumor cell spread and its prognostic significance. J Clin Oncol. 19:1970–1975. 2001. View Article : Google Scholar : PubMed/NCBI
27	Shibue T and Weinberg RA: EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. Nat Rev Clin Oncol. 14:611–629. 2017. View Article : Google Scholar : PubMed/NCBI
28	Voulgari A and Pintzas A: Epithelial-mesenchymal transition in cancer metastasis: Mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta. 1796:75–90. 2009.PubMed/NCBI
29	Chung S, Yao J, Suyama K, Bajaj S, Qian X, Loudig OD, Eugenin EA, Phillips GR and Hazan RB: N-cadherin regulates mammary tumor cell migration through Akt3 suppression. Oncogene. 32:422–430. 2013. View Article : Google Scholar : PubMed/NCBI
30	Qian X, Anzovino A, Kim S, Suyama K, Yao J, Hulit J, Agiostratidou G, Chandiramani N, McDaid HM, Nagi C, et al: N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties. Oncogene. 33:3411–3421. 2014. View Article : Google Scholar : PubMed/NCBI
31	Mitra A, Mishra L and Li S: EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget. 6:10697–10711. 2015. View Article : Google Scholar : PubMed/NCBI
32	Jin YY, Chen QJ, Xu K, Ren HT, Bao X, Ma YN, Wei Y and Ma HB: Involvement of microRNA-141-3p in 5-fluorouracil and oxaliplatin chemo-resistance in esophageal cancer cells via regulation of PTEN. Mol Cell Biochem. 422:161–170. 2016. View Article : Google Scholar : PubMed/NCBI
33	Lagergren J, Smyth E, Cunningham D and Lagergren P: Oesophageal cancer. Lancet. Jun 22–2017.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
34	Yoshida T, Miyoshi T, Seike J, Yamai H, Takechi H, Yuasa Y and Tangoku A: Gene expression changes in a chemoresistant model with human esophageal cancer xenografts using cDNA microarray. Anticancer Res. 29:1163–1168. 2009.PubMed/NCBI
35	Puca R, Nardinocchi L, Givol D and D'Orazi G: Regulation of p53 activity by HIPK2: MOlecular mechanisms and therapeutical implications in human cancer cells. Oncogene. 29:4378–4387. 2010. View Article : Google Scholar : PubMed/NCBI